Organization
AbbVie, North Chicago, IL
2 abstracts
Abstract
Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study.Org: ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, Ministry of Health, Kogarah, NSW, Australia, AbbVie, North Chicago, IL, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy,
Abstract
BIOLOGIC DRUG INITIATORS: REAL WORLD PATTERNS OF MONOTHERAPY AND COMBINATION THERAPY AFTER ONE YEAR Org: CORRONA, Inc., Southborough, MA, AbbVie, North Chicago, IL,